<!doctype html><html><title>Booster Timeline</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=stylesheet href=/css/style.css><link rel=stylesheet href=/css/media.css><body><div class=content><div class="container m-auto"><div class="w-md-55 m-auto mt-2 text-center"><a class="title text-black text-decoration-none" href=/>Booster Timeline</a></div></div><div class="container content m-auto"><div id=article class="w-md-55 m-auto"><div class="mt-1 article-title text-capitalize-letter">Tweets by Eric Topol</div><div class="mt-2 italic post-date">Nov 26, 2021</div><div class="mt-2 article"><div><div class=tweet><div class=profile><a href=https://twitter.com/erictopol/status/1464231697851904005 target=_blank rel=noreferer>06:56 UCT-7</a></div><div class=content>Cases of the B.1.1.529 new variant confirmed in Israel, Belgium<p><a href=https://t.co/9PsPcy1k33>https://t.co/9PsPcy1k33</a></p><p><a href=https://t.co/AacR698G6I>https://t.co/AacR698G6I</a></div></p></div><div class=thread><div class=thread-content>Disappointing from Merck. Updated data for efficacy of their Molnupiravir pill in full trial drops down to 30% from 50%, absolute reduction to 3 from 7 per 100 at interim analysis <a href=https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19/ target=_blank rel=noreferer>https://www.merck.com/news/merck-and-ridgeback-bio ...</a></div><a href=/twitter/erictopol/images/FFIACEPVQAQn54B.png><img src=/twitter/erictopol/images/FFIACEPVQAQn54B.png alt="Twitter image"></img></a><hr><div class=profile><a href=https://twitter.com/erictopol/status/1464237193073807364 target=_blank rel=noreferer>07:18 UCT-7</a></div><div class=content>From the @US_FDA briefing documents along with a lot more data from the clinical trial results<p><a href=https://www.fda.gov/media/154421/download target=_blank rel=noreferer><a href=https://www.fda.gov/media/154421/download>https://www.fda.gov/media/154421/download</a></a></p></div><a href=/twitter/erictopol/images/FFIDtpAVUAIm7Mu.jpg><img src=/twitter/erictopol/images/FFIDtpAVUAIm7Mu.jpg alt="Twitter image"></img></a></div><div class=thread><div class=thread-content>Vaccinations reduce Delta spread:<ol><li><p>Prevention of symptomatic infections; ~95% effectiveness restored w/ boosters.</p></li><li><p>Reduced transmission (27-65%) among people who are vaccinated vs unvaccinated, as seen in multiple recent reports</p></li></ol><p>/1</div><a href=/twitter/erictopol/images/FFIbSrAUYAcRzoe.png><img src=/twitter/erictopol/images/FFIbSrAUYAcRzoe.png alt="Twitter image"></img></a><hr><div class=thread-content>For the latter, setting, variant, & time from vaccination are key determinants</p><p>—Delta transmission > Alpha</p><p>—Prison > Household > Community contacts</p><p>—Longer time from vaccination, less reduction</p><p>—Other factors, such as better viral clearance w/ vaccination, also play a role</p><p>/2</div></p><hr><div class=profile><a href=https://twitter.com/erictopol/status/1464273367800815623 target=_blank rel=noreferer>09:42 UCT-7</a></div><div class=content>Corrected date of citations (typo of 2001)<p>One is from yesterday (Clifford et al) /3</div><a href=/twitter/erictopol/images/FFIkvzHVEAEgduH.png><img src=/twitter/erictopol/images/FFIkvzHVEAEgduH.png alt="Twitter image"></img></a></div></p><div class=tweet><div class=profile><a href=https://twitter.com/erictopol/status/1464280811289468930 target=_blank rel=noreferer>10:12 UCT-7</a></div><div class=content>What is driving the new case records in Germany?<p>The people who aren&rsquo;t vaccinated</p><p><a href=https://www.medrxiv.org/content/10.1101/2021.11.24.21266831v1 target=_blank rel=noreferer><a href=https://www.medrxiv.org/content/10.1101/2021.11.24>https://www.medrxiv.org/content/10.1101/2021.11.24</a> &mldr;</a>
@BenFMaier @DirkBrockmann @rki_de and colleagues</div><a href=/twitter/erictopol/images/FFIqs8iVEAIyvZb.jpg><img src=/twitter/erictopol/images/FFIqs8iVEAIyvZb.jpg alt="Twitter image"></img></a></div></p><div class=thread><div class=thread-content>The @WHO has named B.1.1.529 Omicron, a Variant of Concern [O, not Nu)</div><hr><div class=thread-content>Here's their full statement, summary of data<p><a href=https://t.co/HmkeYvI0mo>https://t.co/HmkeYvI0mo</a></div></p><hr><div class=profile><a href=https://twitter.com/erictopol/status/1464298566810099720 target=_blank rel=noreferer>11:22 UCT-7</a></div><div class=content>This is only the 5th Variant of Concern since the pandemic began: Alpha, Beta, Gamma, Delta, and now Omicron.<p>That it was not named as a Variant of Interest is interesting and raises concern ;-)</p><p>There have been thousands of uninteresting #SARSCoV2 variants</div></p></div><div class=tweet><div class=profile><a href=https://twitter.com/erictopol/status/1464319477714079744 target=_blank rel=noreferer>12:45 UCT-7</a></div><div class=content>Omicron in context, by @Kit_Yates_Maths<p><a href=https://t.co/1PoaqwEyRc>https://t.co/1PoaqwEyRc</a> @Guar</div></p></div><div class=tweet><div class=profile><a href=https://twitter.com/erictopol/status/1464323470217474051 target=_blank rel=noreferer>13:01 UCT-7</a></div><div class=content>Omicron: known and unknowns <a href=https://www.washingtonpost.com/health/2021/11/26/faq-new-variant-omicron/ target=_blank rel=noreferer>https://www.washingtonpost.com/health/2021/11/26/f ...</a>
by @MerylKornfield @lateshiabeachum w/ @Tuliodna @jbloom_lab @BhadeliaMD</div><a href=/twitter/erictopol/images/FFJSMjLVgAA3Dd2.png><img src=/twitter/erictopol/images/FFJSMjLVgAA3Dd2.png alt="Twitter image"></img></a></div><div class=tweet><div class=profile><a href=https://twitter.com/erictopol/status/1464344728950898689 target=_blank rel=noreferer>14:26 UCT-7</a></div><div class=content>Omicron was first detected from a sample collected in Botswana on 11 November<p><a href=https://www.ecdc.europa.eu/en/publications-data/threat-assessment-brief-emergence-sars-cov-2-variant-b.1.1.529 target=_blank rel=noreferer><a href=https://www.ecdc.europa.eu/en/publications-data/th>https://www.ecdc.europa.eu/en/publications-data/th</a> &mldr;</a>
@ECDC_EU via @kakape</p><p>&ldquo;In conclusion, the overall level of risk is assessed as HIGH TO VERY HIGH.&rdquo;</div><a href=/twitter/erictopol/images/FFJkluGUYAIbmrA.jpg><img src=/twitter/erictopol/images/FFJkluGUYAIbmrA.jpg alt="Twitter image"></img></a></div></p><div class=tweet><div class=profile><a href=https://twitter.com/erictopol/status/1464358283452444674 target=_blank rel=noreferer>15:19 UCT-7</a></div><div class=content>From Omicron's sequence, there's a lot of antigenic drift, posing the threat of evading our immune response. Good that vaccine companies are gearing up for it. But we ought to be pressing hard for a pan-sarbecovirus vaccine that would target *all* variants https://t.co/avBeceJvox</div></div><div class=tweet><div class=profile><a href=https://twitter.com/erictopol/status/1464363202649595907 target=_blank rel=noreferer>15:39 UCT-7</a></div><div class=content>RT @trvrb: Growth rate (in absolute terms and relative to Delta) will be become clearer in the following days, but at the moment, I believe…</div></div><div class=thread><div class=thread-content>The mutation map of the 5 Variants of Concern<p>adapted from <a href=https://covariants.org/shared-mutations target=_blank rel=noreferer><a href=https://covariants.org/shared-mutations>https://covariants.org/shared-mutations</a></a></p><p>Omicron (B.1.1.529) shares many key mutations of Alpha, Beta, Gamma & Delta, but a lot more added, very likely having been derived from an immunocompromised host with extensive in vivo evolution</div><a href=/twitter/erictopol/images/FFKhi7yVgAAsyFE.jpg><img src=/twitter/erictopol/images/FFKhi7yVgAAsyFE.jpg alt="Twitter image"></img></a><hr><div class=profile><a href=https://twitter.com/erictopol/status/1464452102382448643 target=_blank rel=noreferer>21:32 UCT-7</a></p></div><div class=content>View of key mutations of Omicron's 50, with 30 in the spike protein, 15 in its receptor binding domain <a href=https://www.ft.com/content/42c5ff3d-e676-4076-9b9f-7243a00cba5e target=_blank rel=noreferer>https://www.ft.com/content/42c5ff3d-e676-4076-9b9f ...</a>
<a href=http://covariants.org target=_blank rel=noreferer>http://covariants.org</a>
@EllingUlrich<p>@_b_meyer</div><a href=/twitter/erictopol/images/FFLF9WeVcA0V7rN.jpg><img src=/twitter/erictopol/images/FFLF9WeVcA0V7rN.jpg alt="Twitter image"></img></a></div></p></div></div><div class=mt-2></div><div class="mt-4 w-md-80 border-top text-default"><div class="d-md-flex d-flex-space-between"><div class="w-md-40 pt-2"><div class="mb-2 text-medium"><a href=https://science-democracy.github.io/twitter/erictopol/11/25/>Previous</a></div></div><div class="w-md-40-max pt-2"><div class="mb-2 text-medium"><a href=https://science-democracy.github.io/twitter/erictopol/11/27/>Next</a></div></div></div></div></div></div></div><div class="container m-auto"><div class="d-flex d-flex-space-between"><div class=mt-4></div></div></div></body></html>